Duramune Adult 3 25 x 1

Duramune Adult 3 25 x 1 Canine vaccine for the prevention of canine distemper, infectious canine hepatitis, canine adenovirus type 2, and canine parvovirus. May be use with dogs older than 6 weeks of age and as a booster vaccine for adult dogs.

DURAMUNE ADULT 3 Fort Dodge Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine Modified Live Virus For subcutaneous vaccination of healthy dogs 6 weeks of age or older as an aid in the prevention of disease caused by canine distemper infectious canine hepatitis canine adenovirus type 2 and canine parvovirus. This product is particularly well suited as a booster vaccination for adult dogs when following an extended vaccination interval program for up to 3 years following initial and booster vaccinations. DIRECTIONS FOR USE General Directions: Aseptically rehydrate this product with Sterile Diluent supplied. Administer one 1 mL dose subcutaneously. Primary Vaccination: A recommended vaccination schedule should start at or about 6 weeks of age. The presence of maternal antibody is known to interfere with the development of active immunity. Puppies should be revaccinated every 2 to 3 weeks until 12 weeks of age. All dogs over 12 weeks of age should initially receive one dose of this product and a second dose 2 to 3 weeks later. Revaccination: Dogs may be vaccinated up to every three years with one dose. The results of the 3 year duration of immunity studies are described in the enclosed package insert. INFOVAX-ID System The INFOVAX-ID System provides a simple and effective method of recording pertinent information on the vaccines administered to animals in a veterinary practice. For vaccines requiring reconstitution remove label from both vials and affix both labels to the animal's medical chart. Using the INFOVAX-ID System: U.S. Pat. No. 5 704 648 1. Grasp the lower right hand corner of the tab at the arrow marked ??Peel Here?? between your thumb and forefinger (figure 1). 2. Pull steadily at a slight upward angle until the top portion of the label is separated from the vial (figure 2). 3. Place the label on the animal's medical chart. Press down on the label to ensure adhesion. CAUTION: Store in the dark at 2 to 7 C (35 to 45 F). AVOID FREEZING. SHAKE WELL. In case of anaphylactoid reaction administer epinephrine. Burn container and all unused contents. Gentamicin added as preservative. EXTENDED DURATION OF IMMUNITY DATA SUMMARY: Canine Parvovirus (CPV)*: Twenty 6-week-old CPV seronegative puppies were vaccinated subcutaneously with two 1 mL doses at an interval of 21 days. A little over three years (164 weeks) after the second vaccination nineteen vaccinated dogs along with the five unvaccinated seronegative control dogs of the same age were challenged with the virulent 2b strain of CPV and observed for post-challenge clinical signs. 100% of the vaccinates showed seroconversion against CPV and remained seropositive through the day of challenge. All of the unvaccinated (100%) control dogs were seronegative to CPV until the day of challenge and susceptible to CPV infection. Following virulent CPV challenge three years after second vaccination 95% of vaccinates were protected and 80% of the non-vaccinated control dogs were susceptible to CPV infection. There were significant differences following virulent CPV challenge between vaccinate and control groups in fecal virus shedding (p=0.0005) lymphopenia (p=0.0007) and number of days of fever (p=0.0051). The results of the long-duration efficacy study demonstrate that the modified live CPV 2b antigen is efficacious and protective in six-weeks of age or older dogs for up to three years following second vaccination. Canine Distemper Virus (CDV)*: Ten six-week-old CDV seronegative puppies were vaccinated five subcutaneously and five intramuscularly with two 1 mL doses at an interval of 21 days. Three years after the second vaccination the ten vaccinated dogs along with the three unvaccinated seronegative controls were challenged with a virulent CDV strain and observed for post-challenge clinical signs. All the vaccinated dogs appeared healthy and active throughout the study period including the 21-day post-challenge observation period. A few of the vaccinates showed only mild and transient clinical signs mostly non-specific to CDV infection during the post-challenge observation period. 100% of the vaccinated dogs showed seroconversion against CDV and remained seropositive through the day of challenge (for 3 years). All the unvaccinated controls were seronegative to CDV on the day of challenge and highly susceptible to CDV infection. Clinical signs of severe multisystemic illness mostly related to CDV infection and high mortality (67%) were observed in the unvaccinated control group. The results of the long-duration efficacy study strongly indicate that the modified live CDV antigen is efficacious and protective in six-weeks of age or older puppies for up to three years following second vaccination. Canine Adenovirus (CAV)*: The CAV fraction of Duramune Adult 3 provides protection against both CAV1 strain (which causes Infectious Canine Hepatitis Virus [ICHV]) and CAV2 strain (which causes respiratory disease). Because the more severe disease form is ICHV an ICHV challenge was selected for the long-term duration of immunity studies. Twelve six-week-old ICHV seronegative puppies were vaccinated nine subcutaneously (SC) and three intramuscularly (IM) with two 1 mL doses at an interval of 21 days. Over three years (36-40 months) after the second vaccination 12 vaccinated dogs along with the 2 unvaccinated seronegative controls were challenged with the virulent strain of ICHV and observed for post-challenge clinical signs. 100% of the vaccinates showed good seroconversion against ICHV following vaccination with significantly high antibody titers on the day of challenge. All the vaccinated dogs appeared healthy and active throughout the study period including the 21-day post-challenge observation period. None of the vaccinates had fever severe clinical signs or loss of body weight following virulent ICHV challenge. Whereas both unvaccinated controls remained seronegative until the day of challenge and susceptible to ICHV infection. The controls showed 100% morbidity with high fever and severe clinical signs following ICHV challenge. The results of the long-duration efficacy study clearly demonstrate that the modified live CAV2 antigen is efficacious and protective in six-week of age or older dogs for up to three years following second vaccination. Ft. Dodge Tech Service Number: 800-533-8536 and press option #2.